0.02
-12.50%
Close of 6 Nov 2026, in SGD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Embracing Future Holdings
Its shares trade on SGX under the ticker 8YY.SI. It has been listed since 19 December 2018. In the fiscal year to 31 December 2025, it reported revenue of SGD 5.3m and a net loss of SGD 4.0m. At that date it held total assets of SGD 5.1m and shareholders' equity of SGD 1.5m.
Biolidics Ltd. is a medical technology company, which engages in the development of diagnostic solutions for healthcare and clinical purposes. The firm's principal activities are technology development, technology transfer, marketing, selling and distribution of biomedical technology, life and medicine science related products and services; provision of laboratory services; and investment holding. The company has three segments: cancer diagnostics, infectious diseases and laboratory services. Cancer diagnostics segment develops and commercializes the ClearCell FX1 System, a fully automated CE-IVD medical device, which separate and enrich cancer cells from blood, allows users of the system to perform liquid biopsies. Infectious diseases segment develops, markets and/or distributes certified test kits with various diagnostic partners. Laboratory services segment offers a range of tests. The laboratory has a regulatory approval from Singapore’s Ministry of Health for molecular microbiology testing and PCR testing services for COVID-19 in Singapore.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 19 Dec 2018
- Employees
- 30
- Website
- biolidics.com ↗
Leadership
Pay as last reported
- Mr. Johnson ChenDirector, Founder, since 2021
- Ian BrownDirector
- Li-Ling Ch'ngDirector
- Zhu HuaDirector
- Joseph LiewDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biolidics Ltd. develops the ClearCell FX1 System for cancer diagnostics in Singapore.
- Cancer diagnostics segment commercializes CE-IVD medical devices for liquid biopsies.
- Laboratory services segment has MOH approval for PCR testing in Singapore.
Weaknesses
- Biolidics Ltd. has only 30 employees in Singapore.
- Cancer diagnostics segment focuses on a single product, the ClearCell FX1 System.
- Infectious diseases segment relies on diagnostic partners for test kits.
Opportunities
- Biolidics Ltd. can expand cancer diagnostics into new markets beyond Singapore.
- Infectious diseases segment can partner with more diagnostic partners for test kits.
- Laboratory services segment can offer molecular microbiology testing globally.
Threats
- Biolidics Ltd. faces competition from other health care companies in Singapore.
- Cancer diagnostics segment must comply with CE-IVD regulations for medical devices.
- Infectious diseases segment depends on external diagnostic partners for test kits.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.